Neurohormonal Parameters in Hypertrophic Cardiomyopathies
REEF-CMH
Evaluation at Rest and Exercise of Clinical, Ultrasonic and Neurohormonal Parameters in Hypertrophic Cardiomyopathies
1 other identifier
interventional
131
1 country
1
Brief Summary
The primary purpose of this study is to demonstrate that changes in plasma levels of circulating neurohormones (mainly BNP and NT-proBNP), measured at rest and post-exercise correlate with exercise functional limitation (assessed by exercise peak VO2) and exercise ultrasonic parameters (as left ventricular filling, obstruction, and mitral regurgitation)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Apr 2009
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2009
CompletedFirst Submitted
Initial submission to the registry
November 15, 2012
CompletedFirst Posted
Study publicly available on registry
November 20, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2013
CompletedMarch 26, 2014
March 1, 2014
4.7 years
November 15, 2012
March 25, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Plasmatic Neurohormonal measures: BNP - NT ProBNP - Troponine
Day 1 at rest and during exercise
Study Arms (1)
single group - consecutive patients
OTHERInterventions
Eligibility Criteria
You may qualify if:
- \- Age 18 to 75 years
- Primary (sarcomeric) hypertrophic cardiomyopathy, obstructive or non obstructive, with studies of exercise peak oxygen consumption and cardiac MRI with gadolinium late-enhancement
- Informed consent
- Patient with a social insurance Patient at rest
- \- Age 18 to 75 years
- Primary (sarcomeric) hypertrophic cardiomyopathy, obstructive or non obstructive
- Informed consent
- Patient with a social insurance
You may not qualify if:
- \- Insufficient echogenicity
- Permanent atrial fibrillation
- Complete BBB on the ECG
- LVEF \< 35 %
- Previous septal ablation (surgical or percutaneous)
- Simultaneous participation to another biomedical research
- If exercise needed:
- contraindication to exercise : hemodynamic instability, uncontrolled high blood pressure (\>220/120 mmHg), severe aortic stenosis
- Inability to exercise (muscular, pulmonary, elderly patient)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hôpital Européen Georges Pompidou
Paris, 75015, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Albert Hagège, MD-PhD
HEGP - Paris
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 15, 2012
First Posted
November 20, 2012
Study Start
April 1, 2009
Primary Completion
December 1, 2013
Study Completion
December 1, 2013
Last Updated
March 26, 2014
Record last verified: 2014-03